The recent failure of AstraZeneca’s interleukin-13 (IL-13) inhibitor tralokinumab to show  efficacy in two phase 3 trials in asthma extends an already lengthy rap sheet against a therapeutic target that has confounded drug developers’ expectations. Despite widespread recognition of the central role IL-13 plays in mediating allergic disease, companies have struggled for more than a decade to produce clear-cut clinical evidence that targeting the cytokine will benefit patients…

Click here to original publication.

Fonte: NATURE BIOTECHNOLOGY VOLUME 36 NUMBER 1 JANUARY 2018